AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02990338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pomalidomide
Description: Pharmaceutical form: capsule Route of administration: oral
Study NCT02990338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
Study NCT02990338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Pharmaceutical form: tablets or solution for infusion Route of administration: oral or intravenous
Study NCT04369599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V/Q System
Description: With the patient supine, sedated, and hemodynamically stable, the Vest is placed upon the patient and secured by clinicians and staff. All chambers of the Vest will be inflated simultaneously. First inflation will be for one hour to a pressure of 0.4 psi. Subsequent inflations at 0.8 and finally 1.2 psi will be performed for one hour each. Participants will be treated for up to four hours and then will be observed for an additional hour.
Study NCT03347786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg Intra-arterial Verapamil
Description: Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
Study NCT03347786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg Intra-arterial Verapamil
Description: Intra-arterial delivery of verapamil following mechanical thrombectomy procedure will be administered at a randomized dose of 10 mg or 20 mg to consenting patients.
Study NCT02359123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cannabics capsules
Description: Cannabis extract in an oil formulation
Study NCT02342171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Convalescent Plasma
Description: Patients will be treated with plasma from recovered EVD patients.
Study NCT00711451 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Manual removal
Description: Manual removal of placenta during cesarean delivery
Study NCT01885897 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ALT-803
Description: Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
Study NCT00711451 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Expressed removal
Description: Surgeon will perform an expressed delivery of the placenta
Study NCT04205591 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: split bone block technique
Description: A graft surgery using autogenous bone chips surrounded by a rigid framework made over the atrophic sites of the mandible and maxilla to obtain bone augmentation to support dental implants
Study NCT04205591 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: split bone block technique
Description: A graft surgery using autogenous bone chips surrounded by a rigid framework made over the atrophic sites of the mandible and maxilla to obtain bone augmentation to support dental implants
Study NCT00122772 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy
Study NCT01226953 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Haemophilus influenzae type b (Hib) vaccine
Description: Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines
Study NCT00122772 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy
Study NCT00122772 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy/Cisplatin
Description: External Beam Radiation 46Gy in 23 daily fractions~High Dose Brachytherapy 2 fractions of 9Gy~Cisplatin 40 mg/sqm weekly
Study NCT00122772 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy/Cisplatin
Description: External Beam Radiotherapy 46Gy in 23 daily fractions~High Dose Brachytherapy 4 fractions of 7Gy~Cisplatin 40mg/sqm weekly
Study NCT00878046 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DePuy Silent™ Hip femoral prosthesis
Description: A short cementless, femoral component for use in total hip arthroplasty
Study NCT06501794 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Quantitative measurement of eye movements
Description: Saccadometer © - diagnostic device: non-invasive quantitative assessment of eye movement
Study NCT01959880 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: The Contour Profile Gel (CPG) breast implants
Description: The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement.~The Contour Profile Gel is available in sizes 125cc - 690cc and 4 styles with various projection and height options in this study.
Study NCT04039022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AXS-05 (dextromethorphan and bupropion) oral tablets
Description: Oral tablets, taken twice daily for up to 12 months.
Study NCT03210363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Biological samples
Description: Blood sample
Study NCT04257838 — intervention group
Intervention type: DRUG
Intervention: Piperacillin/tazobactam or Meropenem
Description: The plasmatic levels determinations will always be made in state of equilibrium (after the fourth dose) and two samples will be collected:~1. Just before the antibiotic infusion (T0)~2. In the midpoint of time (T50). If the antibiotic is administered every 8 hours this determination will be made at 4 hours. If the antibiotic is administered every 6 hours, the determination will be made at 3 hours.~A second complete determination will be made (before the infusion, in the midpoint of time and before the next dose) after the administration of 4 doses as long as a posology modification is made as a consequence of the information received from the plasmatic levels.
Study NCT03126292 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit Down and Play
Description: Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
Study NCT03126292 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Child Safety Handout
Description: Handout regarding early child safety
Study NCT03124303 — intervention group
Intervention type: PROCEDURE
Intervention: High Density-Electroencephalogram
Description: EEG is a safe non-invasive technology without complications that may be used to help diagnose delirium
Study NCT03124303 — intervention group
Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: MRI scan of brain
Study NCT03124303 — intervention group
Intervention type: PROCEDURE
Intervention: Blood specimen collection
Description: Blood will be collected from participants
Study NCT03124303 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pupillometry
Description: A pupillometer is a device that measures the size of the pupils.
Study NCT02313545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IZN-6NVS Cream
Description: IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.~Cream concentration: 5%
Study NCT03510260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group I
Description: Study group I (e-confirmed consent only) will receive an electronic invitation to complete the consent process electronically.The COMRADE questionnaire (our primary outcome) will be obtained prior to the initiation of the traditional consent (as in control group).
Study NCT03510260 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Group II
Description: The study group II will undergo the same intervention as group II but the COMRADE survey questionnaire will be obtained after the paper consent
Study NCT03510260 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Subject will go through the consenting process at the day of surgery at the preop visit as standard in our institution only.
Study NCT04244760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain assessment for verbal patients
Description: The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical and thermal), and psychological state via the completion of questionnaires by the patient.
Study NCT04244760 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pain assessment for non-verbal patients
Description: The pain profile of the patient will be assessed at each time point including biological sample analysis (blood and saliva), quantitative sensory testing (mechanical), and psychological state via the completion of questionnaires by the parent of the patient.
Study NCT01205035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab 2.0mg
Description: Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
Study NCT01225523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel; Cisplatin; 5-Fluorouracil
Description: Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
Study NCT02948231 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mistral implantation
Description: Mistral Implant is implanted in the Mitral valve
Study NCT05552599 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: woolen blanket
Description: Woolen blanket: The people in the experimental group were treated with a standard hospital woolen.
Study NCT02628145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training Intervention
Description: The RTI group will participate in a periodized RT program on 3 non-consecutive days/week using NSCA and ACSM guidelines and will be designed by a team member who is a NSCA certified strength and conditioning specialist. This program will consist of a full-body, nonlinear periodized program: a training method that has frequent variations in program variables. Intensity variations intensity are based on training phase. E.g., the first portion of 12-week cycle has more moderate and light days as participants adapt to the program. Weeks 1-4 will consist of primarily RT machine exercises and few unilateral and multi-joint light free weight exercise. Weeks 5-8 will incorporate more free-weight exercises that are multi-joint. Weeks 9-12 will incorporate more complex multi-joint movements.
Study NCT03922399 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laser and Surgery
Description: Laser and Surgery in patients with major burn scars Evaluating after three years treatment
Study NCT02628145 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Group
Description: The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
Study NCT03000166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step-Up Intervention
Description: Intervention group participants will meet with a study facilitator during 5 regularly scheduled visits for chemotherapy. The facilitator will provide education about the benefits of physical activity and strategies to overcome barriers to physical activity, help the participants to set physical activity goals based on ability and preferences, and educate the participant on using a physical activity tracker.
Study NCT01460537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000mg/m2 as 30-minutes IV infusion
Study NCT01460537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY80-6946
Description: Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
Study NCT01460537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
Study NCT01460537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NaCl
Description: Infusion of 500 ml of 0.9% NaCl over 30-minutes
Study NCT01460537 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY80-6964 fixed dose
Description: BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. \[If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.\]
Study NCT01225523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine
Description: Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
Study NCT02077907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Super Cereal Plus (SC+)
Study NCT02303483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )
Study NCT02303483 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01282554 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electrostimulation program (Rehab 400)
Description: electrostimulation program (Rehab 400) : electrostimulation program during dialysis sessions for 3 months.~Electrostimulation modalities have been chosen to seek both slow and fast muscle fibers : 35 Hz ; impulsion time: 400 µsec ; on/ off : 7'' contraction / 8'' relaxation. Stimulated muscles are quadriceps. Electrostimulation time will be 30 minutes. Each patient will individually regulate work intensity, maximal intensity should be the maximal tolerable intensity.~Electrostimulation will be done 3 times per week. In case of asthenia or medical condition, electrostimulation can be delayed. The program will take place for 3 months.
Study NCT03689088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Goldfish
Description: Goldfish will be placed in the eye for 24h monitoring
Study NCT03689088 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tonometry
Description: Fellow eye will be measured by tonometry
Study NCT02077907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Super Cereal (SC), fortified oil, sugar
Study NCT04150757 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal ketamine
Description: Patients with vaso-occlusive episode and sickle cell disease in moderate to severe pain determined at triage will receive intranasal ketamine while awaiting IV placement.
Study NCT03142997 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: we will perform lung ultrasound for both groups to calculate lung score.
Study NCT02101606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)
Description: TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
Study NCT02175563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Audiovisual feedback from smartphone based app
Study NCT02605863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: 160 mg by mouth daily for 12 months
Study NCT03551418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Watching a video
Description: Watching a video of an adult with DS washing his hands
Study NCT02137434 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary calcium
Description: Dietary calcium from skimmed milk
Study NCT02137434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Supplementary calcium
Description: Supplementary calcium from calcium carbonate
Study NCT04681664 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High fat diet
Description: 50 % fat
Study NCT00004154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide
Description: 200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
Study NCT00004154 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two placebo capsules for 25 days of 28 day cycle.
Study NCT04177654 — intervention group
Intervention type: DRUG
Intervention: Benzimidazoles
Description: A single dose of benzimidazole drug (400mg Albendazole or 500mg Mebendazole) will be administered as part of routine deworming services.
Study NCT02077907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Plumpy Sup
Study NCT02077907 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Corn Soy Blend 14 (CSB14) and fortified oil
Study NCT03443492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Intervention is administered to patients in this Arm.
Study NCT03443492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin(oral )
Description: Intervention is administered to patients in this Arm.
Study NCT03443492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Intervention is administered to patients in this Arm.
Study NCT03443492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Intervention is administered to patients in this Arm.
Study NCT03443492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intervention is administered to patients in this Arm.
Study NCT03443492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: Intervention is administered to patients in this Arm.
Study NCT03443492 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin(IV)
Description: Intervention is administered to patients in this Arm.
Study NCT02033902 — intervention group
Intervention type: DRUG
Intervention: Perampanel
Description: Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
Study NCT02152618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parent Management Training - Oregon Model (PMTO)
Description: Evidence-based, behavioral parent management training model, Parent Management Training - Oregon Model (PMTO) tailored to address permanency barriers of parents of children with SED.
Study NCT00326872 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib Maleate
Study NCT02786160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: HMO
Study NCT02786160 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dextropur
Study NCT04044573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transperineal Focal Laser Ablation (TPLA)
Description: The intervention will take place in an ambulatory setting of the interventional radiology department using the combined Echolaser XVG system. The treatment consists of a local anesthesia to the perineal region. Within each needle, an optic fiber of 300um will be inserted. Each ablation lasts 6 minutes and each fiber ablates1800J at a power of 2-3W. At the end of the ablation there is a pull-back of about 1cm from the original ablation location. According to the dimension of the middle lobe of the prostate, multiple pullbacks can be used. The total ablation is 3600J for 2 fibers (1800J/ fiber) at the power of 2-3W for a total duration of about 30minutes. At the end of the treatment, a 20mg bolus of i.v. corticosteroid is given for anti-edema and anti-inflammatory effects. Antibiotic therapy (Ciprofloxacin 500mg and gastroprotective therapy is given for 5 days. After an adequate amount of time for observation, the patient is dismissed.
Study NCT00642993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH 497079
Description: 100 mg capsule administered orally
Study NCT00642993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules matching SCH 497079 administered orally
Study NCT00756171 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colesevelam
Description: 2 times 3 625 mg tablets daily, 3 weeks
Study NCT00756171 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 times 3 625mg tablets daily